IntrinsicIntrinsic
← All summaries

GridAI Technologies Corp.

GRDX
Financials & Chart →

Business Summary

GridAI Technologies Corp. is a diversified technology and life sciences company operating in two principal areas: energy orchestration and grid optimization software solutions through its subsidiary Grid AI Corp., and legacy biopharmaceutical development activities centered on Adrulipase for the treatment of exocrine pancreatic insufficiency . The Company's primary strategic focus has shifted towards AI-driven energy technology operations following a significant strategic transformation in 2025 .

Grid AI Corp. develops software and services designed to accelerate power availability and optimize energy infrastructure for artificial intelligence (AI) data centers and other large energy users . This platform aims to use and optimize distributed energy resources, including battery energy storage systems, on-site generation, and grid interconnections . Currently, there is no revenue generated from this AI data center platform . Grid AI Corp.'s commercial pipeline is developing through consulting-led engagements and targeted business development initiatives, with current discussions primarily with battery energy storage system (BESS) providers and energy infrastructure participants such as Mango Power and Nomad Transportable Power Systems . Grid AI Corp. does not have any major customers at the present time and aims to primarily serve AI data center developers, hyperscalers, and energy infrastructure developers in North America and Australia .

The Company's legacy biopharmaceutical focus is Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency (EPI), including those with cystic fibrosis (CF) and chronic pancreatitis (CP) . The Company plans to continue development activities relating to Adrulipase . Adrulipase is intended to address EPI using a recombinant, non-porcine lipase approach, which management believes is a meaningful differentiating feature . The Company is no longer developing the Latiglutenase, CypCel, Capeserod, or Niclosamide programs .

For the year ended December 31, 2025, the Company reported total revenue of $36,251 , compared to no revenue for the year ended December 31, 2024 . The cost of services for 2025 was $693,683 , resulting in a gross loss of $(657,432) . Operating expenses totaled $6,426,006 , comprising research and development expenses of $925,482 and general and administrative expenses of $5,500,524 . The loss from operations was $(7,083,438) . Other income (expense), net, was $443,422 , leading to a loss from continuing operations before income taxes of $(6,640,016) . After an income tax benefit of $398,736 , the loss from continuing operations was $(6,241,280) . The loss from discontinued operations was $(312,298) , resulting in a net loss of $(6,553,578) . The net loss applicable to common shareholders was $(6,729,894) , with basic and diluted loss per share of $(4.16) . As of December 31, 2025, cash and cash equivalents were $899,784 , and the accumulated deficit was $208,780,662 . Total current liabilities were $15,159,321 , and notes payable were $2,027,184 .

Revenue for the year ended December 31, 2025, was approximately $36,000 , compared to no revenue in 2024 , entirely reflecting the post-acquisition inclusion of the Grid AI and AMPX business . Cost of services in 2025 was approximately $694,000 , also related to the Grid AI and AMPX business, with no comparable costs in 2024 . Research and development expenses decreased by approximately $21,000, or 2.4% , from $903,941 in 2024 to $925,482 in 2025 , reflecting a shift from legacy life sciences development to technology and platform development within Grid AI Corp. and AMPX . General and administrative expenses decreased by approximately $9,217,000, or 62.6% , from $14,717,333 in 2024 to $5,500,524 in 2025 , primarily due to the absence of significant transaction-related, advisory, legal, and non-cash costs recorded in 2024 in connection with the ImmunogenX transaction . Net loss improved by approximately $11,506,000, or 63.8% , from $(18,059,336) in 2024 to $(6,553,578) in 2025 .

On September 30, 2025, the Company completed a share exchange transaction to acquire 100% of Grid AI Corp., which owned 75% of AMPX UK Holdings . This acquisition materially changed the Company's business profile, shifting its primary strategic focus toward AI-driven energy technology operations . Effective December 1, 2025, the Company changed its name to GridAI Technologies Corp. and its Nasdaq trading symbol to "GRDX" . In March 2025, the Company entered into a rescission agreement with ImmunogenX, LLC, which closed on December 31, 2025, unwinding the prior acquisition of ImmunogenX . The Company retained approximately $695,814 of ImmunogenX accounts payable , while ImmunogenX remained responsible for approximately $9.3 million of secured debt . The Company also discontinued its Capeserod and Niclosamide programs, terminating its license agreement with Sanofi for Capeserod on February 26, 2025 . During the fourth quarter of 2025, Jason Sawyer became Chief Executive Officer, and the Company experienced significant management and board changes, including director resignations, one of which was accompanied by stated disagreements regarding governance, diligence, and disclosure matters .

Business Outlook

The Company expects its revenue profile to differ materially from prior periods due to the inclusion of the Grid AI Corp. and AMPX business . With respect to its retained legacy biopharmaceutical operations, the Company has not generated revenue from product sales and does not expect to do so unless and until a product candidate receives regulatory approval and is successfully commercialized . The Company may also seek to generate revenue in the future from strategic relationships, licensing arrangements, milestone payments, service arrangements, grants, or other sources, though there is no assurance such revenue will be realized .

Grid AI Corp. plans to generate revenue from its AI data center platform through base platform fees for operational visibility and orchestration and performance-based fees tied to power cost optimization . The platform is designed to deliver AI-optimized infrastructure by integrating data center operations with advanced energy systems, including data integration across site-level assets, real-time monitoring, historical data access, reporting capabilities, and a proprietary digital twin model for simulation . Target customers include enterprise and government entities operating large data center campuses . A majority of Grid AI Corp.'s projected 2026 revenues are expected to be derived from the AI data center technology, with the contribution from this platform expected to increase substantially in subsequent years . Grid AI Corp. markets its legacy technologies and intends to pursue commercial deployment of its AI data center platform through direct sales and strategic partnerships with energy developers, system integrators, engineering firms, and other industry participants . Initial development and integration activities for the data center orchestration platform are ongoing in connection with a potential future deployment at a customer site, though the platform has not yet been commercially deployed .

Operating expenses are expected to continue to evolve as management allocates resources among the continued evaluation and potential advancement of Adrulipase, the operation, enhancement, and expansion of the Grid AI Corp. and AMPX business, and corporate, compliance, integration, and public-company requirements . General and administrative expenses are expected to remain significant and may increase in future periods due to supporting the Grid AI Corp. and AMPX business, public company obligations, and expansion of administrative and operational infrastructure .

The Company's future capital needs will depend on factors including the operating requirements of the GridAI and AMPX business, corporate overhead, debt service obligations, public company costs, and the extent to which Adrulipase development activities are pursued . The Company's liquidity is expected to remain dependent on access to outside capital . Additional funds may be sought through public or private offerings of equity or debt securities, warrant exercises, strategic transactions, commercial partnerships, licensing arrangements, asset sales, or other financing alternatives .

Risk Factors

The Company faces substantial doubt about its ability to continue as a going concern due to significant operating losses, negative cash flows, and a substantial accumulated deficit of approximately $208.8 million . The Company's level of indebtedness, including a revolving note with an 18% per annum interest rate that matured on January 31, 2026, and for which a demand for repayment of $1,014,675 was issued on April 1, 2026, could adversely affect its financial condition . The Company will require substantial additional financing to achieve its goals, and a failure to obtain necessary capital could force delays or termination of development programs . Additional offerings may dilute existing stockholders, particularly given the Series H Non-Voting Convertible Preferred Stock issued in the Grid AI Corp. transaction, which is convertible into a substantial number of common shares . Significant board and management turnover during the fourth quarter of 2025, including a director resignation with stated disagreements regarding governance, diligence, and disclosure, could adversely affect the business . Disruptions in the global economy and supply chains, including geopolitical events like the war in Ukraine and conflicts in the Middle East, may materially adversely affect operations, access to capital, and third-party relationships . The planned acceptance of digital assets, including stablecoins, as consideration may expose the Company to volatility, regulatory uncertainty, and accounting complexity . The Company's energy technology business, acquired in 2025, introduces new risks related to software development, systems integration, device interoperability, market participation, and evolving regulatory frameworks . Grid AI Corp.'s limited operating history and dependence on a limited number of customers or projects in the near term, such as Amp Z, which is a related party and has not yet finalized a definitive commercial agreement or generated material revenue , pose risks to revenue generation . The use of artificial intelligence in Grid AI Corp.'s business presents risks of accuracy issues, unintended biases, and increased regulatory and cybersecurity risks . The Company's failure to maintain compliance with Nasdaq's continued listing requirements, including the failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2025, could result in delisting .

Management Priorities

Management's message to shareholders emphasizes a significant strategic transformation in 2025, pivoting the Company's primary strategic focus towards AI-driven energy technology operations through the acquisition of Grid AI Corp. and AMPX, while narrowing its legacy biopharmaceutical activities to Adrulipase . The Company acknowledges its dependency on external funding and is exploring various potential strategies, including raising capital, restructuring indebtedness, and evaluating strategic alternatives, but provides no assurance that these efforts will be successful or lead to increased stakeholder value . Management highlights that a majority of Grid AI Corp.'s projected 2026 revenues are expected to be derived from the AI data center technology, with substantial increases in subsequent years . The Company also notes its current non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the late filing of its Annual Report on Form 10-K for the year ended December 31, 2025, and intends to submit a plan to regain compliance within 60 calendar days, with a potential extension until October 12, 2026 .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 7, MD&A — Overview
  3. [3] Item 1, Business — Our Grid Optimization Software Solutions
  4. [4] Item 1, Business — Our Grid Optimization Software Solutions
  5. [5] Item 1, Business — Our Grid Optimization Software Solutions
  6. [6] Item 1, Business — Our Grid Optimization Software Solutions
  7. [7] Item 1, Business — Dependence on Major Customers
  8. [8] Item 1, Business — Our Grid Optimization Software Solutions
  9. [9] Item 1, Business — Our Legacy Biopharmaceutical Activities
  10. [10] Item 1, Business — Our Legacy Biopharmaceutical Activities
  11. [11] Item 1, Business — Adrulipase
  12. [12] Item 1, Business — Our Legacy Biopharmaceutical Activities
  13. [13] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  14. [14] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  15. [15] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  16. [16] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  17. [17] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  18. [18] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  19. [19] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  20. [20] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  21. [21] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  22. [22] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  23. [23] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  24. [24] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  25. [25] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  26. [26] Item 7, MD&A — Consolidated Results of Operations for the Years Ended December 31, 2025 and 2024
  27. [27] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  28. [28] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  29. [29] Item 7, MD&A — Liquidity and Capital Resources
  30. [30] Item 7, MD&A — Liquidity and Capital Resources
  31. [31] Item 8, Consolidated Balance Sheets
  32. [32] Item 8, Consolidated Balance Sheets
  33. [33] Item 7, MD&A — Revenues
  34. [34] Item 7, MD&A — Revenues
  35. [35] Item 7, MD&A — Revenues
  36. [36] Item 7, MD&A — Cost of Services
  37. [37] Item 7, MD&A — Cost of Services
  38. [38] Item 7, MD&A — Research and Development Expenses
  39. [39] Item 7, MD&A — Research and Development Expenses
  40. [40] Item 7, MD&A — Research and Development Expenses
  41. [41] Item 7, MD&A — Research and Development Expenses
  42. [42] Item 7, MD&A — General and Administrative Expense
  43. [43] Item 7, MD&A — General and Administrative Expense
  44. [44] Item 7, MD&A — General and Administrative Expense
  45. [45] Item 7, MD&A — General and Administrative Expense
  46. [46] Item 7, MD&A — Net Loss
  47. [47] Item 7, MD&A — Net Loss
  48. [48] Item 7, MD&A — Net Loss
  49. [49] Item 7, MD&A — Overview
  50. [50] Item 7, MD&A — Overview
  51. [51] Item 7, MD&A — Acquisition of GridAI Corp. and Corporate Rebranding
  52. [52] Item 7, MD&A — Overview
  53. [53] Item 7, MD&A — Overview
  54. [54] Item 7, MD&A — Overview
  55. [55] Item 7, MD&A — Overview
  56. [56] Item 1, Business — Management and Governance Changes
  57. [57] Item 7, MD&A — Revenue
  58. [58] Item 7, MD&A — Revenue
  59. [59] Item 7, MD&A — Revenue
  60. [60] Item 1, Business — AI Data Center Developed Technology
  61. [61] Item 1, Business — AI Data Center Developed Technology
  62. [62] Item 1, Business — AI Data Center Developed Technology
  63. [63] Item 1, Business — AI Data Center Developed Technology
  64. [64] Item 1, Business — AI Data Center Developed Technology
  65. [65] Item 1, Business — AI Data Center Developed Technology
  66. [66] Item 7, MD&A — Research and Development Expense
  67. [67] Item 7, MD&A — General and Administrative Expense
  68. [68] Item 7, MD&A — Liquidity and Capital Resources
  69. [69] Item 7, MD&A — Liquidity and Capital Resources
  70. [70] Item 7, MD&A — Liquidity and Capital Resources
  71. [71] Item 1A, Risk Factors — Our current dependency on external funding for our operations raises a substantial doubt about our ability to continue as a going concern.
  72. [72] Item 7, MD&A — Revolving Loan Agreement
  73. [73] Item 1A, Risk Factors — Our level of indebtedness and our ability to make payments on or service our indebtedness could adversely affect our business, financial condition, results of operations, cash flow and liquidity.
  74. [74] Item 1A, Risk Factors — We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product candidate development programs, testing efforts or other operations, including.
  75. [75] Item 1A, Risk Factors — Additional offerings in the future may dilute then existing stockholders’ percentage ownership of our Company.
  76. [76] Item 1A, Risk Factors — We experienced significant board and management turnover during the fourth quarter of 2025, and instability in governance and leadership could adversely affect our business.
  77. [77] Item 1A, Risk Factors — Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations.
  78. [78] Item 1A, Risk Factors — Acceptance of digital assets, including stablecoins, as consideration in our transactions may expose us to volatility, regulatory uncertainty and accounting complexity, which could adversely affect our financial results.
  79. [79] Item 1A, Risk Factors — Our energy technology business exposes us to risks that are different from our historical biopharmaceutical business.
  80. [80] Item 1, Business — Dependence on Major Customers
  81. [81] Item 1A, Risk Factors — Our near-term revenue from our GridAI business may depend on a limited number of customers, projects, or counterparties, and the loss, delay, or failure to convert pilot programs or letters of intent into long-term commercial agreements could materially adversely affect our financial condition and results of operations.
  82. [82] Item 1A, Risk Factors — Grid AI Corp. plans to use artificial intelligence in its business, and challenges with properly managing its use could result in harm to our brand, reputation, business or customers, and adversely affect our results of operations.
  83. [83] Item 1A, Risk Factors — Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our Common Stock.
  84. [84] Item 7, MD&A — Overview
  85. [85] Item 1A, Risk Factors — Our current dependency on external funding for our operations raises a substantial doubt about our ability to continue as a going concern.
  86. [86] Item 1, Business — AI Data Center Developed Technology
  87. [87] Item 7, MD&A — Nasdaq Listing Matters

Analysis on 5/21/2026